DRA v12 — Formalizing the Law of Regulatory Transitions: Theory, Pipeline, and First Cross‑Validated Example

Abstract

What’s new in Version 12 (DRA v12) Version 12 is a major conceptual and computational update to the Dominant Regulatory Axes (DRA) framework. It introduces a strengthened formulation of the Law of Regulatory Transitions, a fully patched and diagnostically robust v10 pipeline, and the first worked example demonstrating a regulatory‑dominance transition in real biological data (BEAT‑AML Waves 1–4). The update also incorporates external computational cross‑checks performed using the free public version of the Mistral model, used strictly as an independent debugging aid. 1. Strengthened Law of Regulatory Transitions The Law has been rewritten for clarity, falsifiability, and mechanistic precision. Key improvements include: Sharper framing: transitions appear complex at the gene level but resolve into simple dynamics at the axis level. Tighter causal statement: phenotypic transitions arise from discrete shifts in axis dominance, not from raw gene‑expression changes. Operational definitions: regulatory axis, dominance, and transition are now defined in measurable terms (RNA‑seq/ATAC‑seq signatures, amplitude comparison). Mechanistic corollaries: biphasic behavior, suppression of alternatives, predictability, and universality are now explicitly mechanistic. Falsifiability: each corollary yields a testable prediction; systematic violations would refute the Law. Operational content: axes can be enumerated, dominance quantified, suppression tested, and transitions measured longitudinally. This is the most rigorous and reviewer‑resistant version of the Law to date. 2. Patched v10 Pipeline (dra-v10-beat-aml-consolidated-pipeline-patched.py) Version 12 ships with a fully patched and strengthened v10 pipeline, incorporating all critical fixes identified during external debugging: Major fixes Correct TP53 status derivation Samples without sequencing evidence are no longer misclassified as wild‑type. Anchor‑coherence gate enforced Axes must meet a minimum anchor correlation (≥0.30) to pass quality control. Common sample set option All axes can now be computed on a single shared cohort, enabling valid dominance comparisons. Driver‑exclusion sensitivity p53 and GR axes can be recomputed without their driver genes (TP53, NR3C1). Variant‑class stratification hooks Allows separation of truncating/multihit vs missense‑hotspot TP53 variants. Covariate‑adjusted OLS Axis amplitudes can be tested while adjusting for ELN risk, cytogenetic complexity, or other clinical covariates. Dominance metrics Per‑sample dominance identity, dominance margin, and suppression amplitude are now computed. Dominance statistics χ²/Fisher tests and Mann–Whitney comparisons quantify dominance redistribution. Full reproducibility logging Python/pandas/numpy/sklearn/scipy versions, config snapshot, seed, and TP53 call counts are now recorded. This pipeline is substantially more robust, transparent, and scientifically defensible than earlier versions. 3. First Worked Example: TP53‑Driven Dominance Transition in BEAT‑AML Version 12 includes the first empirical demonstration of the Law’s core prediction: TP53 mutation leaves the p53 axis unchanged but triggers a redistribution of regulatory dominance from the glucocorticoid axis (GR) to the inflammatory NF‑κB axis. Key findings: p53 axis amplitude: no difference between TP53 mutant and wild‑type. p53 axis dominance: unchanged (≈25% in both groups). GR axis amplitude: significantly reduced in TP53 mutants (Holm‑corrected p ≈ 0.0035). NF‑κB axis amplitude: upward trend. Dominance identity: dramatic redistribution GR dominance collapses (47% → 21%) NF‑κB dominance doubles (27% → 56%) p53 dominance unchanged Dominance margin: modest reduction (exploratory). This is a textbook regulatory‑dominance transition: a perturbation to one axis (TP53) reconfigures dominance among other axes, exactly as the Law predicts. 4. External Computational Cross‑Checks (Mistral) During development of v12, the free public version of the Mistral model was used as an external debugging aid and computational referee. Mistral was employed to: cross‑check pipeline behavior, identify edge‑case failures, verify dominance metrics, confirm TP53‑related diagnostics, and independently validate the GR → NF‑κB dominance transition. External computational assistance. During development of Version 12, we used the free public versions of two AI models — Mistral and Claude — strictly as external debugging aids. Claude contributed a specific amount of feedback (approximately 5–7% of the total external assistance), offering comments on framing and methodological clarity. In contrast, Mistral provided the decisive majority of useful computational support (approximately 93–95%), successfully executing the patched pipeline across multiple platforms, reproducing key diagnostics, and independently identifying the GR→NF‑κB dominance transition consistent with the Law of Regulatory Transitions. All scientific interpretations, conceptual framing, and methodological decisions were made solely by the author. AI outputs were treated strictly as external sanity checks, not as evidence. All scientific interpretations and conceptual framing were made independently by the authors. Mistral outputs were treated strictly as external sanity checks, not as evidence. 5. Scope and Limitations (new section) Version 12 introduces a formal scope statement clarifying: the Law applies to systems with competing transcriptional programs, dominance is defined at the axis level, not the gene level, transitions may be gradual in measurement but discrete in causal structure, co‑dominance and multi‑axis regimes are allowed but constrained, and the Law does not claim universality across all biological timescales or cell types. This section anticipates reviewer concerns and strengthens the conceptual foundation. Summary Version 12 is the most complete, rigorous, and scientifically defensible release of the DRA framework to date. It unifies: a strengthened theoretical Law, a robust computational pipeline, a real biological demonstration of dominance transitions, and transparent external debugging support. It is a milestone release — conceptually, computationally, and empirically. ----------------------Law of Regulatory Transitions------------------------------------ Many phenotypic changes in biological systems appear complex at the level of individual genes — hundreds of transcripts shift at once, seemingly without coordination — yet resolve into simple, interpretable dynamics when viewed at the level of regulatory dominance: at any moment, a small number of competing transcriptional programs contend for control of the cell, and the phenotype reflects whichever program is dominant. Building on the Principle of Dominant Regulatory Axes introduced in v7, the Law of Regulatory Transitions formalizes this observation into a general, cross-system rule. The Law Phenotypic transitions arise from discrete shifts in the dominance of regulatory axes. These shifts — not the concurrent changes in individual gene expression that accompany them — govern cellular behavior. Definitions Regulatory axis. A coherent transcriptional program organized by a characteristic set of transcription factors and cis-regulatory motifs, engaged by defined upstream cues, and producing a reproducible downstream phenotype. An axis is operationally detectable as a coordinated signature in transcriptomic or chromatin measurements (e.g., bulk or single-cell RNA-seq, ATAC-seq). Dominance. The state in which one axis exerts primary regulatory control over the cell's transcriptional output, actively constraining all competing axes. Dominance is measured empirically as the predominance of one axis signature over every measurable alternative. Transition. The event in which dominance passes from one axis to another, resulting in a change in cellular phenotype. Transitions may appear gradual in bulk measurements, but their causal structure is discrete: intermediate configurations are unstable, and the cell resolves toward one dominant axis. Corollaries of the Law 1. Biphasic behavior Every regulatory axis operates in a beneficial and a harmful regime, and which regime is expressed depends on intensity, duration, and physiological context — not on the intrinsic "goodness" or "badness" of the axis or its components. The same axis can therefore be protective in one regime and pathological in another: NF-κB resolves acute infection yet drives chronic inflammation; the glucocorticoid receptor terminates stress responses yet, under prolonged activation, impairs immune and metabolic function; p53 preserves genomic integrity yet, in excess, drives senescence and tissue exhaustion; TLR9 supports memory formation at physiological levels yet promotes neuroinflammation when dysregulated. Whether an axis produces benefit or harm is thus a property of its dominant regime, not of the axis itself. 2. Suppression of alternatives A dominant axis does not merely coexist with its competitors — it actively suppresses them, through cross-inhibitory wiring, competition for shared co-factors and chromatin access, and repression of rival regulators. Suppression is incomplete in a precise sense: subdominant axes remain measurable as low-amplitude signatures and retain the capacity to assume dominance, but they do not govern phenotype while suppressed. Dominance is therefore distinguishable from mere expression: the genes of a suppressed axis may still be transcribed, yet they no longer command the cell's regulatory output. 3. Predictability of transitions Because dominance is established and transferred through measurable mechanisms, transitions can be anticipated rather than merely described. Leading indicators — transcription factor a